Search Our Scientific Publications & Authors

Gynecol Oncol Rep 2020 Aug 16;33:100585. Epub 2020 May 16.

University of Cincinnati Department of Obstetrics & Gynecology: Division of Gynecologic Oncology, 234 Goodman Street, Cincinnati, OH 45219, USA.

Primary vaginal endometrioid adenocarcinoma is a rare cancer that is often associated with chronic endometriosis. We present the case of a 72-year-old female who underwent right salpingo-oophorectomy followed by hysterectomy with benign pathology 25 years prior to her cancer diagnosis. She had an extensive surgical history in the intervening years and several complicating factors including a history of endometriosis as well as a recurrent peritoneal inclusion cyst treated with ethanol sclerotherapy, followed by formation of a peritoneal-vaginal fistula. Read More

Urology 2020 Apr 22. Epub 2020 Apr 22.

Department of Urology, University of Kentucky, Lexington, KY. Electronic address:

Urothelial cell carcinoma of the bladder is exceedingly rare in pediatric patients. Based on current literature, bladder cancer in this population is thought to be low-grade, noninvasive, and unlikely to recur, suggesting significant biologic differences when compared to the adult population. This is a 15-year-old male diagnosed with low-grade urothelial cell carcinoma with subsequent multifocal recurrence on surveillance cystoscopy managed by induction and maintenance intravesical Bacillus Calmette-Guerin. Read More

J Urol 2020 Apr 21:101097JU0000000000001084. Epub 2020 Apr 21.

Fundacio Puigvert, Dept of Urology, Barcelona, Spain.

Purpose: Detection of MCM5 containing cells in urine has been shown to be indicative for the presence of a bladder tumour in primary diagnosis. The objective of this study was to evaluate diagnostic performance of ADXBLADDER in patients undergoing cystoscopic surveillance in Non Muscle Invasive Bladder Cancer (NMIBC) follow-up.

Materials And Methods: A multicentric prospective blinded study was carried out at 21 European centres in patients undergoing cystoscopy for NMIBC surveillance, diagnosed in the preceding 2 years. Read More

Curr Opin Urol 2020 May;30(3):387-391

Department of Urology, Radboudumc Nijmegen, Nijmegen, The Netherlands.

Purpose Of Review: Patients with nonmuscle invasive bladder cancer (NMIBC) have a high risk of recurrent tumors, even in spite of contemporary guideline recommended therapy. Follow-up recommendations are also clear (cystoscopy with cytology and upper urinary tract imaging in high-risk patients), but frequency and duration of follow-up are well defined. However, recent developments in follow-up tools might be of interest for clinical practice. Read More

BMC Urol 2020 Feb 11;20(1):12. Epub 2020 Feb 11.

Capital & Coast District Health Board, Wellington, New Zealand.

Background: Surveilling recurrent urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance.

Objective: To audit the clinical utility of a new surveillance protocol incorporating the Cxbladder Monitor (CxbM) test in real-world practice. Read More

Int Braz J Urol 2020 Mar-Apr;46(2):224-233

Disciplina de Urologia, Faculdade de Medicina do ABC, Santo André, SP, Brasil.

Introduction: Considering the lack of data on BC trends in Brazilian population, mainly as a result of the difficulty on gathering data, the present manuscript provides an overview of bladder cancer incidence, hospitalization, mortality patterns and trends using the Brazilian Data Center for The Public Health System (DATASUS).

Materials And Methods: All hospital admissions associated with BC diagnosis (ICD-10 C67) between 2008 and 2017 were analyzed. Distributions according to year, gender, age group, ethnicity, death, length of hospital stay, and costs were evaluated. Read More

J Urol 2020 05 10;203(5):902-909. Epub 2019 Dec 10.

Department of Urology, University of Iowa, Iowa City, Iowa.

Purpose: Rescue intravesical therapies for patients with bacillus Calmette-Guérin failure nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel therapy has shown safety and efficacy in 2 retrospective, single institution cohorts. This doublet has since been adopted as an intravesical salvage option at multiple institutions. Read More

Int J Clin Oncol 2020 Jan 15;25(1):165-174. Epub 2019 Nov 15.

PSMAR-IMIM Research Institute, Carrer del Dr. Aiguader, 88, Barcelona, Spain.

Background: The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial cancer (UC) that progressed after first-line platinum-containing chemotherapy, compared with standard chemotherapy (paclitaxel, docetaxel, or vinflunine). Pembrolizumab is approved for patients with bladder cancer in Japan.

Patients And Methods: Analysis was performed in the subgroup of Japanese patients enrolled in the KEYNOTE-045 study. Read More

World J Urol 2019 Nov 5. Epub 2019 Nov 5.

Department of Urology, Istituto Clinico Humanitas IRCCS-Clinical and Research Hospital, via Manzoni 56, 20089, Milan, Rozzano, Italy.

Purpose: To investigate the clinical performance of a new mRNA-based urine test, aiming to avoid unnecessary follow-up cystoscopy in patients under active surveillance (AS) for recurrent NMIBC.

Methods: This is a prospective cohort study enrolling patients with history of low-grade (LG) NMIBC, who developed a recurrence during the follow-up and underwent AS. Their urinary samples were analyzed by Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA). Read More

Diagn Pathol 2019 Oct 21;14(1):113. Epub 2019 Oct 21.

Department of Pathology, University of Michigan Medical School, 2800 Plymouth Rd, Building 35, Ann Arbor, MI, 48109, USA.

Background: Rapid ("warm") autopsies of patients with advanced metastatic cancer provide important insight into the natural history, pathobiology and histomorphology of disease in treatment-resistant tumors. Plasmacytoid urothelial carcinoma (PUC) is a rare variant of urothelial carcinoma characterized by neoplastic cells morphologically resembling plasma cells. PUC is typically aggressive, high-stage at presentation, and associated with poor outcomes. Read More

Ann Surg 2019 11;270(5):899-905

Objective: To determine factors associated with outcomes following pelvic exenteration for advanced nonrectal pelvic malignancy.

Background: The PelvEx Collaborative provides large volume data from specialist centers to ascertain factors associated with improved outcomes.

Methods: Consecutive patients who underwent pelvic exenteration for nonrectal pelvic malignancy between 2006 and 2017 were identified from 22 tertiary centers. Read More

J Urol 2020 02 24;203(2):283-291. Epub 2019 Sep 24.

Department of Urology, Amsterdam University Medical Center, University of Amsterdam, The Netherlands.

Purpose: The objective of this study was to assess the value of fluorescence in situ hybridization to predict early recurrence in patients with nonmuscle invasive bladder cancer at intermediate and high risk treated with bacillus Calmette-Guérin.

Materials And Methods: We performed a systematic review using MEDLINE®, Embase® and the Cochrane Library. Individual patient data from prospective observational studies of fluorescence in situ hybridization in patients treated with bacillus Calmette-Guérin were included. Read More

Medicine (Baltimore) 2019 Aug;98(31):e16223

Department of Urology and Renal Transplantation.

Intravesical instillation of Bacille Calmette-Guèrin (BCG) is the standard adjuvant treatment for high-risk non muscle invasive bladder cancer (NMIBC). Since its mechanism of action is supposed to be linked to the immune system efficiency and senescence could negatively affect this efficiency, BCG efficacy in the elderly has been questioned. This study aimed to assess the impact of age on BCG efficacy and safety in patients with high-grade T1 bladder cancer (BC). Read More

Cancer Sci 2019 Sep 23;110(9):2822-2833. Epub 2019 Jul 23.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Kinesin family member C1 (KIFC1) is implicated in the clustering of multiple centrosomes to maintain tumor survival and is thought to be an oncogene in several kinds of cancers. In our experiments, we first performed bioinformatics analysis to investigate the expression levels of KIFC1 in bladder cancer (BC) specimens and normal bladder epitheliums and then, using our samples, verified findings by quantitative real-time PCR and western blotting assays. All data showed that KIFC1 was significantly upregulated in BC specimens at both the mRNA and protein levels. Read More

Eur Urol Oncol 2019 Nov 22;2(6):723-729. Epub 2019 Jun 22.

Urologic Sciences, The University of British Columbia, Vancouver, Canada.

Recurrent low-grade Ta tumours, classified as intermediate-risk non-muscle-invasive bladder cancer (NMIBC), have a high risk of recurrence but a low risk of progression. This case presents a 60-yr-old female with intermediate-risk NMIBC who has been treated with sequential courses of mitomycin C followed by bacillus Calmette-Guérin (BCG). She continued to develop multiple episodes of recurrence. Read More

Future Oncol 2019 Jul 25;15(19):2267-2275. Epub 2019 Jun 25.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11351, Egypt.

To assess mortality from bladder cancer following a diagnosis of nonmuscle-invasive bladder cancer. This is a SEER registry-based study. The risk of death from bladder cancer was compared with that of the general population. Read More

J Urol 2019 10 6;202(4):682-688. Epub 2019 Sep 6.

Department of Urology, School of Medicine and Public Health and Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin.

Purpose: We evaluated the AUA (American Urological Association)/SUO (Society of Urologic Oncology) nonmuscle invasive bladder cancer risk model to predict nonmuscle invasive bladder cancer recurrence and progression prior to death.

Materials And Methods: We performed a retrospective analysis using electronic medical records and cancer registry data of patients with nonmuscle invasive bladder cancer in a multicenter United States patient population. We evaluated recurrence-free and progression-free survival according to the AUA/SUO nonmuscle invasive bladder cancer risk model. Read More

Eur Urol Oncol 2018 10 5;1(5):437-442. Epub 2018 Jun 5.

Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy.

Background: It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC).

Objective: To update a previous preliminary series and investigate pathological outcomes for patients who failed to remain on AS.

Design, Setting, And Participants: Prospective observational cohort study started in February 2008, and currently still active, at a tertiary university hospital, including patients with pathologically confirmed NMIBC who experienced recurrence during follow-up. Read More

BJU Int 2019 11 2;124(5):746-757. Epub 2019 Jul 2.

Department of Urology and Transplantation Surgery, Edouard Herriot Hospital, Lyon, France.

Objectives: To evaluate the oncological and functional outcomes of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after low-dose-rate (LDR) brachytherapy.

Patients And Methods: Clinical phase II studies (2003-2015) included 50 consecutive patients with post-brachytherapy local recurrence treated by S-HIFU. S-HIFU was performed with post-external beam radiotherapy (EBRT) parameters and, since 2008, with specific post-brachytherapy parameters. Read More

Scand J Urol 2019 Apr - Jun;53(2-3):109-115. Epub 2019 May 8.

d Department of Urology , Landspitali University Hospital , Reykjavik , Iceland.

In non-muscle-invasive bladder cancer (NMIBC), local recurrence after transurethral resection of the bladder (TURB) is common. Outcomes vary between urological centres, partly due to the sub-optimal surgical technique and insufficient application of measures recommended in the guidelines. This study evaluated early recurrence rates after primary TURB for NMIBC before and after introducing a standardized treatment protocol. Read More

Transl Androl Urol 2019 Feb;8(1):54-60

Department of Urology, Bichat Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.

Most of low grade (LG) bladder tumors will experience disease recurrence and very few of them (<2%) will experience disease progression. Therefore active surveillance (AS) for LG non-muscle invasive bladder cancer (NMIBC) has emerged. The goal of our study was to provide a literature review of AS for LG NMIBC including inclusion criteria, modalities and oncological outcomes. Read More

Eur Urol 2019 07 8;76(1):9-13. Epub 2019 Apr 8.

Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France. Electronic address:

FGFR3 is one of the most frequently mutated genes in bladder cancer and a driver of an oncogenic dependency. Here we report that only the most common recurrent FGFR3 mutation, S249C (TCC→TGC), represents an APOBEC-type motif and is probably caused by the APOBEC-mediated mutagenic process, accounting for its over-representation. We observed significant enrichment of the APOBEC mutational signature and overexpression of AID/APOBEC gene family members in bladder tumors with S249C compared to tumors with other recurrent FGFR3 mutations. Read More

Int J Surg Pathol 2019 Aug 11;27(5):483-491. Epub 2019 Mar 11.

1 Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia.

Urothelial cancer is a heterogeneous disease with different molecular pathways that produce distinct molecular subtypes with specific characteristics and patient survival outcomes that require different therapeutic methods. Urothelial tumors in young patients appear to have distinct genetic features compared with their counterparts in older patients. Using a Lund subtype-specific immunohistochemistry panel, we performed molecular subtype profiling of an urothelial carcinoma case series (n = 49) in patients younger than 45 years of age. Read More

Support Care Cancer 2019 Oct 14;27(10):3877-3885. Epub 2019 Feb 14.

Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, Toronto, Canada.

Background: To date, little research has examined the quality of life and cancer-associated needs of bladder cancer patients. The objective of the current study was to assess the quality of life (QoL), informational needs, and supportive care needs (SCN) in a large sample of muscle invasive (MIBC) and non-muscle invasive (NMIBC) bladder cancer survivors across the treatment trajectory (newly diagnosed and undergoing treatment, post-treatment follow-up, and treatment for advanced/recurrent disease).

Methods: Questionnaires were distributed to a convenience sample of patients registered with Bladder Cancer Canada, the Princess Margaret Cancer Centre, or The Ottawa Hospital. Read More

Cancer Epidemiol Biomarkers Prev 2019 04 30;28(4):782-788. Epub 2019 Jan 30.

Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.

Background: The high rate of non-muscle-invasive bladder cancer recurrence is a major challenge in patient management. miRNAs functionally regulate tumor cell proliferation and invasion, and have strong potential as biomarkers because they are robust to degradation. The objective of this project was to identify reproducible prognostic miRNAs in resected non-muscle-invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype. Read More

BJU Int 2019 06 5;123(6):959-967. Epub 2019 Feb 5.

Department of Urology, Medical University of Vienna, Vienna, Austria.

Objectives: To investigate prospectively the clinical utility and influence on decision-making of Bladder EpiCheck™, a non-invasive urine test, in the surveillance of non-muscle-invasive bladder cancer (NMIBC).

Materials And Methods: Urine samples from 440 patients undergoing surveillance for NMIBC were prospectively collected at five centres and evaluated using the Bladder EpiCheck test (NCT02647112). A multivariable nomogram and decision-curve analysis (DCA) were used to evaluate the impact of Bladder EpiCheck on decision-making when used in routine clinical practice. Read More

Nat Commun 2019 01 16;10(1):253. Epub 2019 Jan 16.

Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, 75005, Paris, France.

The upregulation of PPARγ/RXRα transcriptional activity has emerged as a key event in luminal bladder tumors. It renders tumor cell growth PPARγ-dependent and modulates the tumor microenvironment to favor escape from immuno-surveillance. The activation of the pathway has been linked to PPARG gains/amplifications resulting in PPARγ overexpression and to recurrent activating point mutations of RXRα. Read More

Proteomics Clin Appl 2019 03 30;13(2):e1800148. Epub 2019 Jan 30.

Proteomics Laboratory, Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.

Purpose: To evaluate the diagnostic and prognostic performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) in detecting urinary bladder cancer (UBC).

Methods: The Integrated Study on Bladder Cancer (n = 571; mean age:69.4 ± 12. Read More

J Ovarian Res 2019 Jan 10;12(1). Epub 2019 Jan 10.

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan, Republic of China.

Background: The value of this report is the identification of late recurrence with an extremely unusual combination of malignant transformation. In particular, the retroconversion of immature to mature teratoma as well as a somatic-type malignant transformation were both observed postchemotherapeutically in our case.

Case Presentation: We report the case of a 20-year-old girl who completed fertility-sparing surgery and chemotherapy under the diagnosis of ovarian mixed germ cell tumor (immature teratoma and yolk sac tumor) and experienced subsequent recurrence 4 years after a second debulking surgery with a somatic type malignant transformation (teratoma with melanoma and leiomyosarcoma). Read More

Transplant Proc 2018 Dec 30;50(10):3694-3697. Epub 2018 Jun 30.

Division of Transplantation, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN.

Although the relationship between immunosuppression and cancer risk is well-documented, the association between immunosuppression and the development of preneoplastic lesions (PNL) is less clear. PNLs pose a unique clinical conundrum in the transplanted pancreas because their prevalence in the general population is not infrequent. We present the case of a 58-year-old man with a history of diabetes mellitus type 1 who underwent successful pancreas transplantation with bladder drainage. Read More

Eur Urol 2019 05 12;75(5):853-860. Epub 2018 Dec 12.

Radboudumc, Nijmegen, The Netherlands.

Background: A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC.

Objective: To validate Xpert characteristics in patients previously diagnosed with non-muscle-invasive BC. Read More

Urology 2019 02 23;124:179-182. Epub 2018 Oct 23.

Urology Service, Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Objective: To determine tumor recurrence rate of low-grade, papillary, and non-muscle-invasive (TaLG) bladder tumors in patients who have asymptomatic bacteriuria (ABU). Microbes in the urine trigger immune responses like intravesical Bacillus Calmette-Guerin, suggesting that common bacteria may also exert an antitumor effect.

Methods: We investigated recurrence rates in 387 patients with low-grade, papillary noninvasive bladder tumors TaLG, with or without ABU. Read More

Environ Mol Mutagen 2019 03 4;60(2):168-173. Epub 2018 Oct 4.

Grup de Mutagènesi, Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08193, Barcelona, Spain.

It has been suggested that the frequency of micronuclei (MN) in defoliated urothelial cells could be used as a biomarker for both the potential risk of bladder cancer (BC) and its progression. To prove this we have carried out a large study evaluating the MN frequency in a group of 383 hospital patients submitted to cystoscopy. From them, 77 were negative in their first cystoscopy, and were considered as a reference group; 79 were positive and were classified as patients with tumor; and 227 with previous bladder cancer submitted to follow-up monitoring were negative and classified as BC patients without tumor. Read More

Curr Opin Urol 2018 11;28(6):557-562

Department of urology, University of Rochester School of Medicine, Rochester, New York, USA.

Purpose Of Review: To describe the importance of risk stratification and the role of more conservative management like office fulguration, office laser ablation and active surveillance in recurrent low-grade Ta tumours.

Recent Findings: Updated models have been designed for risk stratification of intermediate-risk tumours. Conservative forms of management like office fulguration or laser ablation and even active surveillance seem well tolerated; however, randomized, controlled trials are lacking. Read More

Radiology 2018 10;289(1):267-271

From the Departments of Radiology (A.D.d.L., D.N.C., I.P.), Urology (I.P.), and Pathology (F.F.), and the Advanced Imaging Research Center (D.N.C., I.P.), University of Texas Southwestern Medical Center, 2201 Inwood Rd, 2nd Floor, Suite 202, Dallas, TX 75390-9085.

History A 68-year-old man with a remote history of a previously resected high-grade urothelial carcinoma in the renal pelvis was being observed and was undergoing urologic treatment for recurrent low-grade urothelial carcinoma of the bladder. During his most recent evaluation, he reported no specific symptoms and denied experiencing hematuria, dysuria, or abdominal pain. At routine surveillance MRI of the abdomen and pelvis (images not shown), a lesion was noted in the peripheral zone of the prostate gland. Read More

Curr Urol Rep 2018 Sep 13;19(11):94. Epub 2018 Sep 13.

Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Purpose Of Review: There are an estimated 33 million men and women with overactive bladder (OAB) in the USA. Despite the prevalence of OAB, it remains a frequently misdiagnosed condition. OAB has shared symptomatology with other common urologic conditions, namely recurrent urinary tract infections (UTIs). Read More

Harefuah 2018 Aug;157(8):507-510

Department of Urology, Hadassah Hebrew University Hospital, Jerusalem.

Objectives: To report our experience with the active surveillance policy in patients with recurrent low-risk bladder tumors.

Methods: The files of 52 patients who underwent active surveillance instead of immediate surgical resection were reviewed. Different variables concerning tumor growth rate were evaluated. Read More

Am J Kidney Dis 2018 12 23;72(6):790-797. Epub 2018 Aug 23.

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address:

Rationale & Objectives: Kidney stones have been associated with increased risk for end-stage renal disease (ESRD). However, it is unclear whether there is also an increased risk for mortality and if these risks are uniform across clinically distinct categories of stone formers.

Study Design: Historical matched-cohort study. Read More

Cell Physiol Biochem 2018 16;48(6):2364-2373. Epub 2018 Aug 16.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background/aims: This study aimed to validate the value of urothelial stem cell (USC) markers ΔNp63, integrin β4, CD47, and CD44v6 in predicting the prognosis of non-muscle invasive bladder cancer (NMIBC) located in different anatomic regions of bladder.

Methods: The study reviewed the clinicopathologic data of 169 patients with NMIBC. Using real-time PCR and immunohistochemistry, the expression of ΔNp63, integrin β4, CD47, and CD44v6 in archived specimens of patients with NMIBC were validated. Read More

Bladder Cancer 2018 Jul 30;4(3):303-310. Epub 2018 Jul 30.

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Objectives: To investigate the role of fluid intake from beverages before and after a diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence.

Study Design: Prospective cohort study.

Methods: 716 patients with non-muscle invasive bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour (TURBT) and completed self-administrated questionnaires on usual fluid intake from beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over the year after diagnosis), were included. Read More

World J Urol 2019 Jan 14;37(1):51-60. Epub 2018 Aug 14.

Division of Urology, McGill University Health Center-Glen Site, 1001 Decarie Blvd, Montreal, QC, H3A 3J1, Canada.

Purpose: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC).

Methods: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. Read More

Abdom Radiol (NY) 2019 01;44(1):234-238

Department of Radiology, University of Pennsylvania, 3400 Spruce Street, 1 Silverstein, Philadelphia, PA, 19104, USA.

Purpose: To compare frequency of new and recurrent urothelial cell carcinoma (UCC) among patients with and without pseudodiverticulosis on imaging.

Methods: This retrospective case-control study compared all 113 sequential patients with ureteral pseudodiverticulosis on radiographic urography between 1/1/2002 and 12/31/2012. Six patients were lost to follow-up. Read More

G Chir 2018 Jul-Aug;39(4):195-207

Colovesical fistula (CVF) is an abnormal communication between bowel and urinary bladder. Main causes are represented by complicated diverticular disease, colonic and bladder cancer and iatrogenic complications. Diagnosis is often based on patognomonic signs: faecaluria, pneumaturia and recurrent urinary tract infections. Read More

Ann Oncol 2018 12;29(12):2302-2312

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address:

Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis comprised ∼8% of new cancer cases in the USA in 2016. In the metastatic setting, 15% of patients exhibit long-term survival following cisplatin-based chemotherapy and in patients with recurrent disease, response rates to second-line chemotherapy are generally 15%-20% with a 3-month progression-free survival. However, recent advances in immunotherapy represent an opportunity to significantly improve patient outcomes. Read More

Am J Surg Pathol 2018 10;42(10):1286-1296

Department of Pathology, Johns Hopkins Medical Institute, Baltimore, MD.

Prostatic adenocarcinoma with focal pleomorphic giant cell features is rare with the only prior series consisting of 6 cases. From 2005 to 2018, we identified 29 cases from our consult service and 1 case from our own institution. Men ranged in age from 39 to 90 years (median=75. Read More

BMC Gastroenterol 2018 Jun 14;18(1):83. Epub 2018 Jun 14.

Department of Gastroenterology, Sheffield Teaching Hospitals, Northern General Hospital, Herries Road, Sheffield, S5 7AU, England.

Background: Adenocarcinomas can arise in a variety of circumstances in which intestinal segments have been used for urinary diversions. Whereas ureterosigmoidostomy is the oldest and simplest form of continent urinary diversion it also seems to be the most dangerous in this regard. Herein we present a case of colonic neoplasia complicating a non-functioning ureterosigmoidostomy after 55 years; the longest latent period documented to date. Read More

BJU Int 2018 12 26;122(6):1010-1015. Epub 2018 Jul 26.

Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria.

Objective: To investigate the oncological outcome of nonagenarians with bladder cancer, as a substantial rise in bladder cancer in the old-old age group in the upcoming decades is expected, due to demographic changes and the peak incidence around the age of 85 years. The paucity of data of nonagenarians prompted us to investigate the outcomes of such patients.

Patients And Methods: A retrospective, multicentre study was designed to assess patient demographics, tumour patterns, treatment strategies and outcome in patients aged ≥90 years treated at participating centres. Read More

Am J Surg Pathol 2018 07;42(7):971-976

Departments of Pathology.

Urothelial carcinoma in situ (CIS) of the bladder with glandular differentiation (CIS-GL) is rare with some showing an association with small cell carcinoma. There is a paucity of data on whether CIS-GL diagnosed in the absence of invasive carcinoma is associated with an increased risk of developing small cell carcinoma of the bladder. Twenty-seven cases of CIS-GL were identified from the consult files of one of the authors from 2008 to 2015 without prior or coexisting invasive carcinoma at the time of diagnosis. Read More

Cancer Causes Control 2018 06 17;29(6):573-579. Epub 2018 Apr 17.

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Introduction: There is some evidence that greater consumption of fruit and vegetables decreases the risk of bladder cancer. The role of fruit and vegetables in bladder cancer recurrence is still unknown.

Objective: The role of total fruit and vegetable intake in relation to the risk of developing bladder cancer recurrence in a prospective cohort study. Read More